US FDA approves AstraZeneca’s Truqap plus Faslodex to treat HR-positive breast cancer
AstraZeneca secured the FDA approval based on positive results from Phase 3 CAPItello-291 clinical trial that evaluated the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Nov 23
AstraZeneca secured the FDA approval based on positive results from Phase 3 CAPItello-291 clinical trial that evaluated the…
17 Nov 23
Casgevy is a genetically modified autologous CD34+ cell-enriched population that contains human hematopoietic stem and progenitor cells, edited…
17 Nov 23
The opening of Lilly's first significant production complex in Germany is aligned with the strategy to produce essential…
17 Nov 23
The indicated use is for the initial treatment of adults diagnosed with locally advanced unresectable or metastatic human…
17 Nov 23
The agreement includes upfront funding, and milestone payments, in addition to royalties on any approved products arising from…
16 Nov 23
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Nov 23
Under the expanded collaboration, Kite has also exercised its option to negotiate a licence for Arcellx’s ARC-SparX programme,…
16 Nov 23
The approval was based on the results from the TRIDENT-1 Phase 1/2 trial in which 79% of people…
15 Nov 23
Autifony will lead the drug discovery and preclinical development activities on the two ion channel targets associated with…
15 Nov 23
The combination failed to improve progression-free survival (PFS) against CRT alone in NSCLC patients and showed an enhanced…